Open AccessThe Use of Anticonvulsant Adjuncts to Treat Alcohol Withdrawal Syndrome in Older Adults
Author(s) -
Stefanie Montgomery,
Karen Dahri,
Kaveh Rayani,
Jacqueline Kwok,
Peter Chan
Publication year - 2022
Publication title -
canadian geriatrics journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.682
H-Index - 21
ISSN - 1925-8348
DOI - 10.5770/cgj.25.544
Subject(s) - medicine , benzodiazepine , dosing , adverse effect , alcohol withdrawal syndrome , medical prescription , anticonvulsant , anesthesia , emergency medicine , alcohol , psychiatry , pharmacology , epilepsy , biochemistry , chemistry , receptor
Background We evaluated the prescribing practices of anticonvulsant (AC) adjuncts to benzodiazepines in managing Alcohol Withdrawal Syndrome (AWS). We also examined the prescription of relapse prevention agents for Alcohol Use Disorder (AUD), and adverse events related to AWS treatment. Methods Records were reviewed retrospectively pertaining to medically ill adults aged 60 and above with AWS and admitted to a medicine or hospitalist unit of a Canadian centre between June 2013 and June 2018. Duration and dosing of benzodiazepine, dosing and type of AC and AUD agent, and adverse events were collected. A multivariable regression model was employed. Results 83 encounters were included in the study and 28 were prescribed an AC. The amount and duration of benzodiazepine administered were not statistically different between the benzodiazepine only and the AC adjunct groups, once severe AWS complications were accounted for. Five new prescriptions of traditional AUD agents were provided on discharge. No AC-associated adverse events occurred. Conclusions AC adjuncts for AWS did not decrease the amount of benzodiazepine administered nor shorten the duration of treatment. Their routine use is not supported by our findings. Our study highlights a missed opportunity for AUD agents to be prescribed during hospitalization.